Please provide your email address to receive an email when new articles are posted on . The updated label includes 3-year data in which 20.1% of treated patients achieved sustained complete renal ...
Supernus Pharmaceuticals, Inc. announced that the FDA has approved an updated label for Qelbree (viloxazine extended-release capsules) to include new pharmacodynamic data, highlighting its serotonin 5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback